Monoclonal antibody therapy shows great promise in the fight against “bad” cholesterol
March 25th, 2012
Comments off
A study published March 22 in the New England Journal of Medicine shows how a monoclonal antibody reactive to a serine protease (PCSK9) may have significant therapeutic potential. Developed by Regeneron and Sanofi.
Evan A. Stein, M.D., Ph.D., Scott Mellis, M.D., Ph.D., George D. Yancopoulos, M.D., Ph.D., Neil Stahl, Ph.D., Douglas Logan, M.D., William B. Smith, M.D., Eleanor Lisbon, M.D., M.P.H., Maria Gutierrez, M.D., Cheryle Webb, M.D., Richard Wu, Ph.D., Yunling Du, Ph.D., Therese Kranz, R.N., M.B.A., Evelyn Gasparino, B.S., and Gary D. Swergold, M.D., Ph.D. N Engl J Med 2012; 366:1108-1118. March 22, 2012.
Link to paper here.